Nymox Pharmaceutical

What Nymox Pharmaceutical does

Nymox Pharmaceutical Corporation is a pre-revenue biopharmaceutical company developing therapeutics and diagnostics targeted at the aging male population. Founded in 1995 and originally headquartered in Irvine, California, the company re-domiciled to the Bahamas in 2015 and announced a planned headquarters relocation to Zug, Switzerland in 2018. Nymox currently lists on OTCQB under symbol NYMXF after being suspended from NASDAQ in July 2023 for failure to maintain the $1.00 minimum bid price. The corporate footprint includes operational offices in Irvine, California and St.-Laurent, Quebec, and a headcount of 1-10 employees.

The company's lead asset is Fexapotide Triflutate (branded NYMOZARFEX), a novel protein injectable designed to induce apoptosis (programmed cell death) selectively in overproliferated prostate glandular cells. It is administered as a single painless injection directly into the prostate under routine ultrasound guidance in an office procedure, with no anesthesia required. Completed Phase 3 clinical trials enrolled over 1,700 men across more than 70 US clinical centers, including a 997-patient long-term follow-up cohort demonstrating statistically significant lasting symptom improvement over 7 years. A Phase II study (NX03-0040) of 146 patients is evaluating FT for low-grade localized prostate cancer. Nymox also markets two diagnostic products — NicAlert® and TobacAlert® — which are test strips that measure salivary or urinary biomarkers of tobacco exposure.

Nymox operates a pre-approval, R&D-heavy business model. The company has filed marketing authorization applications with the FDA (received a Refusal to File letter in May 2022), the UK MHRA, the Danish DKMA (now requiring resubmission), and five European Union member states, but has not yet received commercial marketing authorization in any major market. Revenue is not publicly disclosed and the company is pre-revenue; operations have historically been funded through a series of private placements and registered direct offerings totaling roughly $50M+ from 2014 to 2023, including a $16.25M raise in April 2018 and a $2M insider-led placement in August 2023 from board member James Robinson. In June 2026, the company announced a partnership with the Global Alliance of Regenerative Medicine (GARM) on Roatan Island, Caribbean, to make NYMOZARFEX available to medical tourists — the drug's first public commercial channel. Pricing for the drug has not been publicly disclosed.

Name

Nymox Pharmaceutical

Legal name

Nymox Pharmaceutical Corporation

Website

https://nymox.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

1–10 employees

Short description

Nymox Pharmaceutical Corporation is a pre-revenue biopharmaceutical company developing Fexapotide Triflutate (NYMOZARFEX), a single-injection protein therapy for benign prostatic hyperplasia and low-grade localized prostate cancer, plus NicAlert and TobacAlert tobacco-exposure diagnostics.

Ownership category

akta.pro rank

Product category

Urological Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

Keywords

• Biopharmaceutical therapeutics
• Prostate disease treatment
• Injectable drug development
• Diagnostic test kits
• Clinical-stage pharmaceuticals

Headquarters

HQ city

Montreal

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical drug sales: Once regulatory approval is obtained, Nymox plans to generate revenue through the sale of its Fexapotide Triflutate (NYMOZARFEX) drug for the treatment of BPH and low-grade localized prostate cancer. The company is pre-revenue with no approved products currently on the market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Nymox Pharmaceutical Corporation is developing Fexapotide Triflutate (branded NYMOZARFEX), a novel protein injectable drug administered as a single painless in-office injection for the treatment of benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The company also sells NicAlert and TobacAlert diagnostic test strips that measure tobacco product exposure using saliva or urine samples.

Product overview

Nymox Pharmaceutical Corporation is a pharmaceutical company specializing in therapeutics and diagnostics for the aging male population. The company operates two distinct product lines: (1) Fexapotide Triflutate (branded as Nymozarfex for prostate treatments), a novel injectable drug for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer, representing the company's lead therapeutic candidate currently in regulatory approval process; and (2) NicAlert® and TobacAlert® diagnostic tests for measuring tobacco product exposure. The company has completed Phase 3 clinical trials for Fexapotide involving over 1,700 men across 70+ clinical centers in the US and is pursuing marketing approvals in the US, Europe, and other markets.

Differentiator

Problem solved

Functional benefit

Brands

• Fexapotide Triflutate: A protein injectable drug for benign prostatic hyperplasia (BPH) and low grade localized prostate cancer, administered as a simple injection in the urologist's office.
• Nymozarfex
• NicAlert
• TobacAlert

Products and services

• Fexapotide Triflutate (FT) A novel protein injectable drug for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer, administered as a single painless injection directly into the prostate in a urologist's office under routine ultrasound guidance. It works by inducing apoptosis (programmed cell death) to selectively remove cells in the enlarged prostate gland. Clinical trials involved over 1,700 men across 70+ clinical centers.
• NicAlert A simple, cost-effective diagnostic test strip to determine smoking status using saliva or urine samples. It helps smokers, parents, teachers, and insurance companies verify smoking status.
• TobacAlert A home test providing quick, accurate on-the-spot determination of a person's level of exposure to tobacco products including second-hand smoke. Not intended for medical use.
• Nymozarfex (TM) The brand name for Fexapotide Triflutate when used for prostate treatment. Available at GARM facility on Roatan Island for medical tourists seeking prostate care alternatives.

Quantifiable outcome

• Gleason Grade Progression Reduced by 81% Overall in prostate cancer study
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Global Alliance of Regenerative Medicine (GARM)coreChannel Partner/ Reseller/ Distributor · 17 June 2026Nymox entered into a formal agreement with GARM to offer its Nymozarfex(TM) drug treatment for prostate conditions at GARM's facility on Roatan Island in the Western Caribbean. Certified expert urologists provide the treatment, targeting medical tourists seeking alternatives to existing drugs with side effects or surgical treatments.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Merck & Co. Merck markets Proscar (finasteride), the foundational 5-alpha reductase inhibitor for BPH, and is the historical market leader in chronic BPH pharmacotherapy.
• Eli Lilly: Eli Lilly markets Cialis (tadalafil), approved for both BPH and erectile dysfunction, and is a broad incumbent pharma with the commercial reach and resources to dominate urology.
• GlaxoSmithKline: GSK markets Avodart (dutasteride), a 5-alpha reductase inhibitor for BPH, and is one of the entrenched incumbents in the long-term medical management of enlarged prostate.
• Boston Scientific: Boston Scientific acquired NxThera and commercializes the Rezum system, a leading minimally invasive BPH treatment using convective water vapor energy, making it a major incumbent alternative to Fexapotide.
• Astellas Pharma: Astellas markets Rapaflo (silodosin), a leading branded alpha-blocker for BPH, and is a broad incumbent in urology pharmaceuticals with the scale to dominate any market Nymox enters.
• Sumitomo Pharma America (formerly Urovant Sciences): Sumitomo acquired Urovant Sciences, which markets Gemtesa (vibegron) for overactive bladder, making it a focused urology commercial player whose specialty-pharma model parallels what Nymox aspires to be.

Direct peers

• Veru Inc. Veru (formerly Sophiris Bio) developed Topsalysin/PRX302, a similar targeted injectable protein therapy for BPH, representing the closest mechanistic and clinical comparator to Nymox's Fexapotide Triflutate.

Emerging players

• Procept BioRobotics: Procept markets the Aquablation system, a robotic waterjet-based focal therapy for BPH, positioning it as a minimally invasive office-based alternative competing for the same urology patient segment.
• HistoSonics: HistoSonics is developing histotripsy, a non-thermal focused ultrasound platform with prostate applications, representing a novel non-invasive approach to BPH and prostate tissue ablation.
• Lipocine: Lipocine is a small-cap specialty pharma developing men's health products (e.g., testosterone therapies), and is comparable to Nymox as a similarly-sized, publicly-listed urology/endocrinology-focused pharmaceutical company.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nymox-pharmaceutical-corp

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nymox Pharmaceutical